Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients

Phage therapy is recognized as a promising alternative to antibiotics in treating pulmonary bacterial infections, however, its use has not been reported for treating secondary bacterial infections during virus pandemics such as coronavirus disease 2019 (COVID-19). We enrolled 4 patients hospitalized...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nannan Wu, Jia Dai, Mingquan Guo, Jianhui Li, Xin Zhou, Feng Li, Yuan Gao, Hongping Qu, Hongzhou Lu, Jing Jin, Tao Li, Lei Shi, Qingguo Wu, Ruoming Tan, Mingli Zhu, Lan Yang, Yun Ling, Shunpeng Xing, Jianzhong Zhang, Bangxin Yao, Shuai Le, Jingmin Gu, Jinhong Qin, Jie Li, Mengjun Cheng, Demeng Tan, Linlin Li, Yiyuan Zhang, Zhaoqin Zhu, Jinfeng Cai, Zhigang Song, Xiaokui Guo, Li-Kuang Chen, Tongyu Zhu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2021-01-01
coleção:	Emerging Microbes and Infections
Assuntos:	Phage therapy carbapenem-resistant Acinetobacter baumannii nosocomial infections COVID-19
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/22221751.2021.1902754
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!